Treatment of chronic hepatitis C

Yun Jung Chang, Kwan Soo Byun

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Chronic infection with HCV represents second most common cause of end-stage liver diseases and hepatocellular carcinoma in Korea. The introduction of new agents and regimens for the treatment of chronic hepatitis C, such as pegylated forms of interferon-alpha (Peg-IFN) and combination with oral ribavirin has resulted in substantial improvement in sustained virologic response (SVR) rates. SVR rate of Peg-IFN and ribavirin combination therapy can be 40-46% of individuals infected with genotype 1 and approximately 75-85% with genotype 2 and 3. Peg-IFN/ribavirin combination therapy represents current standard therapy of chronic hepatitis C. This article reviews the treatment objectives, outcomes, optimal regimens, efficacy and predictors of response, monitoring during treatment, adverse events, retreatment of persons who failed to respond to previous treatments, and treatment of special patient groups in chronic hepatitis C.

Original languageEnglish
Pages (from-to)301-307
Number of pages7
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume44
Issue number6
Publication statusPublished - 2004 Jan 1

Fingerprint

Chronic Hepatitis C
Ribavirin
Interferon-alpha
Therapeutics
Genotype
End Stage Liver Disease
Retreatment
Korea
Hepatocellular Carcinoma
Infection

Cite this

Treatment of chronic hepatitis C. / Chang, Yun Jung; Byun, Kwan Soo.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 44, No. 6, 01.01.2004, p. 301-307.

Research output: Contribution to journalReview article

@article{7f9c53994f414a09a0b85e97b4e319d9,
title = "Treatment of chronic hepatitis C",
abstract = "Chronic infection with HCV represents second most common cause of end-stage liver diseases and hepatocellular carcinoma in Korea. The introduction of new agents and regimens for the treatment of chronic hepatitis C, such as pegylated forms of interferon-alpha (Peg-IFN) and combination with oral ribavirin has resulted in substantial improvement in sustained virologic response (SVR) rates. SVR rate of Peg-IFN and ribavirin combination therapy can be 40-46{\%} of individuals infected with genotype 1 and approximately 75-85{\%} with genotype 2 and 3. Peg-IFN/ribavirin combination therapy represents current standard therapy of chronic hepatitis C. This article reviews the treatment objectives, outcomes, optimal regimens, efficacy and predictors of response, monitoring during treatment, adverse events, retreatment of persons who failed to respond to previous treatments, and treatment of special patient groups in chronic hepatitis C.",
author = "Chang, {Yun Jung} and Byun, {Kwan Soo}",
year = "2004",
month = "1",
day = "1",
language = "English",
volume = "44",
pages = "301--307",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "6",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C

AU - Chang, Yun Jung

AU - Byun, Kwan Soo

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Chronic infection with HCV represents second most common cause of end-stage liver diseases and hepatocellular carcinoma in Korea. The introduction of new agents and regimens for the treatment of chronic hepatitis C, such as pegylated forms of interferon-alpha (Peg-IFN) and combination with oral ribavirin has resulted in substantial improvement in sustained virologic response (SVR) rates. SVR rate of Peg-IFN and ribavirin combination therapy can be 40-46% of individuals infected with genotype 1 and approximately 75-85% with genotype 2 and 3. Peg-IFN/ribavirin combination therapy represents current standard therapy of chronic hepatitis C. This article reviews the treatment objectives, outcomes, optimal regimens, efficacy and predictors of response, monitoring during treatment, adverse events, retreatment of persons who failed to respond to previous treatments, and treatment of special patient groups in chronic hepatitis C.

AB - Chronic infection with HCV represents second most common cause of end-stage liver diseases and hepatocellular carcinoma in Korea. The introduction of new agents and regimens for the treatment of chronic hepatitis C, such as pegylated forms of interferon-alpha (Peg-IFN) and combination with oral ribavirin has resulted in substantial improvement in sustained virologic response (SVR) rates. SVR rate of Peg-IFN and ribavirin combination therapy can be 40-46% of individuals infected with genotype 1 and approximately 75-85% with genotype 2 and 3. Peg-IFN/ribavirin combination therapy represents current standard therapy of chronic hepatitis C. This article reviews the treatment objectives, outcomes, optimal regimens, efficacy and predictors of response, monitoring during treatment, adverse events, retreatment of persons who failed to respond to previous treatments, and treatment of special patient groups in chronic hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=18244399615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244399615&partnerID=8YFLogxK

M3 - Review article

VL - 44

SP - 301

EP - 307

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 6

ER -